Tuesday, 23 March 2010

43 confirmed post-marketing Natalizumab-related cases of PML

The news of 43 confirmed cases of post-marketing Natalizumab-related PML coincides with the timely publication of the description of the first 28 such cases and a review on the topic:

Clifford DB, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010 Apr;9(4):438-446.

Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010 Apr;9(4):425-437.

These developments underpin the urgent efforts to implement an appropriate risk-stratification strategy to lower the risks of developing PML for people with MS receiving Natalizumab.

Please watch this space for an update.

No comments:

Post a Comment

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.